Antibody Development For Difficult Targets requires innovative screening and engineering to overcome low immunogenicity and hidden epitopes.
This approach blends computational design, targeted library construction, and rigorous validation to deliver high-affinity, specific antibodies for challenging targets in therapeutics and diagnostics.